PureTech’s Vedanta Biosciences gets federal funding for C. Diff. microbiome therapy

PureTech’s Vedanta Biosciences gets federal funding for C. Diff. microbiome therapy

Source: 
Pharmaforum
snippet: 

US biotech Vedanta Biosciences has been awarded up to $76.9 million to develop VE303 for high-risk Clostridioides difficile (C. diff.) infection by a US government agency.